Long-term molecular remission with persistence ofBCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL

How I treat older patients with ALL

(2013) N. Gokbuget   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Properties of end-stage human T cells defined by CD45RA re-expression

(2012) Sian M Henson et al.   CURRENT OPINION IN IMMUNOLOGY

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

(2012) M. Tang et al.   HAEMATOLOGICA

Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

(2011) Kazuma Ohyashiki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

(2011) N. Takahashi et al.   HAEMATOLOGICA

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment

(2009) G. Riva et al.   BLOOD

CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response

(2009) Kensuke Usuki et al.   LEUKEMIA RESEARCH